FDA approves Cabometyx for liver cancer
Exelixis Inc. (NASDAQ:EXEL) said Monday FDA approved Cabometyx cabozantinib to treat hepatocellular carcinoma patients previously treated with Nexavar sorafenib.
The approval comes two months after Exelixis’ partner Ipsen Group (Euronext:IPN; Pink:IPSEY) received approval from the EC for Cabometyx in the indication...
BCIQ Target Profiles
AXL receptor tyrosine kinase (AXL) (UFO)
Vascular endothelial growth factor (VEGF) receptor 1 (FLT1) (VEGFR-1)
Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Vascular endothelial growth factor (VEGF) receptor 3 (FLT4) (VEGFR-3)
c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)